Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanism-based reasoning without systematic methodology
PubMed 18327998 · doi:10.1586/14779072.6.3.391
What was done
This narrative review examined the physiologic mechanisms of action, regulatory status, and clinical implications of prescription omega-3-acid ethyl esters (P-OM3) for treating hypertriglyceridemia.
What was found
The abstract reports no primary quantitative trial outcomes or effect sizes. It notes that prescription omega-3 fatty acids reduce very high triglyceride levels (defined as ≥500 mg/dL [5.65 mmol/L]) primarily by decreasing the synthesis and secretion of very-low-density lipoprotein (VLDL) particles and accelerating triglyceride clearance from VLDL and chylomicrons through lipoprotein lipase upregulation.
Why it matters
The review outlines how omega-3 fatty acids provide a distinct, complementary lipid-lowering mechanism to statins, supporting their combined use in patients with severe hypertriglyceridemia.
Limits
As a narrative review, it lacks a systematic literature search, quality appraisal of included studies, or pooled clinical outcome data in the abstract. The exact molecular mechanisms in humans remain incompletely defined.
Cited by
- supports Lovaza received FDA approval to lower triglycerides by about 20% specifically in patients with baseline triglyceride levels exceeding 500 mg/dL.